OUTSIDE THE US
Serving the global market with in vitro diagnostics (IVDs)
Once we have developed strong clinical evidence and clinician adoption of our tests in the US, we typically look to make them accessible to patients in Europe and beyond. We are doing this by developing them, as appropriate, as IVD tests that can be performed locally by laboratories and hospitals worldwide.
Learn about our innovative test portfolio and plans for expansion
*The Prosigna® Breast Cancer Assay is available in the US on the nCounter® Analysis System as an in vitro diagnostic (IVD) rather than through Veracyte’s centralized labs. The Lymphmark™ test for lymphoma that is currently in development is similarly intended for use in the US as an IVD companion diagnostic.